SG11201809402VA - Technology for efficient activation of nkt cells - Google Patents

Technology for efficient activation of nkt cells

Info

Publication number
SG11201809402VA
SG11201809402VA SG11201809402VA SG11201809402VA SG11201809402VA SG 11201809402V A SG11201809402V A SG 11201809402VA SG 11201809402V A SG11201809402V A SG 11201809402VA SG 11201809402V A SG11201809402V A SG 11201809402VA SG 11201809402V A SG11201809402V A SG 11201809402VA
Authority
SG
Singapore
Prior art keywords
nkt
cell
ligand
nkt cells
positive cell
Prior art date
Application number
SG11201809402VA
Inventor
Masaru Taniguchi
Tomokuni Shigeura
Minako Aihara
Keigo Hanada
Original Assignee
Riken
Ambicion Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Ambicion Co Ltd filed Critical Riken
Publication of SG11201809402VA publication Critical patent/SG11201809402VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Abstract

TECHNOLOGY FOR EFFICIENT ACTIVATION OF NKT CELLS The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-γ 5 production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for 10 producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation 15 containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof. (No drawing to be published)
SG11201809402VA 2016-04-28 2017-04-14 Technology for efficient activation of nkt cells SG11201809402VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016091674 2016-04-28
PCT/JP2017/015383 WO2017188033A1 (en) 2016-04-28 2017-04-14 Technology for efficient activation of nkt cells

Publications (1)

Publication Number Publication Date
SG11201809402VA true SG11201809402VA (en) 2018-11-29

Family

ID=60160376

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809402VA SG11201809402VA (en) 2016-04-28 2017-04-14 Technology for efficient activation of nkt cells

Country Status (11)

Country Link
US (1) US11744860B2 (en)
EP (1) EP3453755B1 (en)
JP (1) JP6447947B2 (en)
KR (1) KR102404040B1 (en)
CN (1) CN109642214A (en)
CA (1) CA3022209A1 (en)
IL (1) IL262553B (en)
MY (1) MY186581A (en)
SG (1) SG11201809402VA (en)
TW (1) TWI764896B (en)
WO (1) WO2017188033A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729321A (en) * 2019-11-19 2022-07-08 迈凯恩技术有限公司 Method for evaluating safety of substance in vitro using human immortalized myeloid cells
WO2022245813A2 (en) * 2021-05-18 2022-11-24 Verdure Biotech, Inc. A method for controlling viral infections through adoptive transfer of a cell product comprising an expanded and enriched population of superctivated cytokine killer cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288291A4 (en) 2000-06-06 2004-05-12 Kirin Brewery Method of amplifying natural killer t cells
EP1916310B1 (en) 2005-06-17 2018-09-26 Riken Method for analysis of nkt cell function
KR101419711B1 (en) 2005-09-08 2014-07-17 가부시키가이샤 메디넷 Method for activation treatment of antigen-presenting cell
EP2133326B1 (en) 2007-02-22 2015-12-23 Riken Novel pseudoglycolipid and use thereof
KR100995340B1 (en) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 Vaccine comprising Monocyte or immature myeloid cellsIMC which was loaded with the ligand of natural killer T cell and antigen
EP2272854B1 (en) 2008-03-25 2015-08-05 Riken Novel glycolipid and use thereof
CN102137796B (en) 2008-08-04 2014-02-26 东洋制罐株式会社 Decorative can body and process for producing the same
US8580751B2 (en) 2008-09-11 2013-11-12 Riken Esterified α-galactosylceramide
WO2011096536A1 (en) 2010-02-05 2011-08-11 独立行政法人理化学研究所 Novel synthetic glycolipid and use thereof
MY171201A (en) * 2012-04-26 2019-10-01 Riken New carbamate glycolipid and use thereof
CA2923579C (en) * 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups

Also Published As

Publication number Publication date
CA3022209A1 (en) 2017-11-02
CN109642214A (en) 2019-04-16
TWI764896B (en) 2022-05-21
EP3453755B1 (en) 2023-06-28
JP6447947B2 (en) 2019-01-09
MY186581A (en) 2021-07-28
IL262553B (en) 2022-03-01
KR102404040B1 (en) 2022-05-31
IL262553A (en) 2018-12-31
WO2017188033A1 (en) 2017-11-02
JPWO2017188033A1 (en) 2018-07-05
US20190134094A1 (en) 2019-05-09
US11744860B2 (en) 2023-09-05
KR20180136540A (en) 2018-12-24
EP3453755A4 (en) 2020-01-22
EP3453755A1 (en) 2019-03-13
TW201803984A (en) 2018-02-01

Similar Documents

Publication Publication Date Title
MX2017014089A (en) Method of culturing.
EP4279579A3 (en) Methods and compositions for natural killer cells
MX2020005907A (en) Serum-free media formulation for culturing cells and methods of use thereof.
WO2015109362A3 (en) Method for reducing total gas production and/or methane production in a ruminant animal
UA113729C2 (en) MUTANT INTERLAYKIN-2 (IL-2) POLYPEPTIDE
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
MY170532A (en) Zinc amino acid complex with cysteine
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
MX2016005658A (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells.
EP2571522A4 (en) Cancer treatment
GB0503936D0 (en) Method
MX2021001716A (en) Novel compositions, their use, and methods for their formation.
AU341638S (en) Single chamber wine chilling and dispersing system
Klammer Les Femme Parlent
AU201816835S (en) Battery
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
MY174654A (en) Method for preparing natural beef flavor
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
SG11201809402VA (en) Technology for efficient activation of nkt cells
WO2014200997A3 (en) Method for preparing three-dimensional, organotypic cell cultures and uses thereof
IL246525B (en) Pomegranate derived cell culture and methods for preparing and using the same
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
MX2020008129A (en) Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof.
MY194572A (en) Self-sufficient process for the production of biomass hydrolysate with reduced salt content
TWD201967S (en) Electric oven